Clinical Trials Browser

Phase 1 × Interventional × Rosuvastatin Calcium × Clear all

NCT02592317 2026-03-13

A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer

Phase 1 Active not recruiting

23 enrolled

Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT07372625 2026-03-12

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

Phase 1 Recruiting

14 enrolled

Other solid neoplasm

TP53 Y220C Mutation

NCT06899061 2026-03-03

Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib

Phase 1 Active not recruiting

41 enrolled

Advanced Solid Malignancies

NCT07088913 2026-03-03

A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants

Phase 1 Completed

20 enrolled

Healthy Participants

NCT07235748 2026-02-17

Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants

Phase 1 Completed

28 enrolled

Healthy Adult Participants

NCT05828303 2025-04-01

A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors

Phase 1 Withdrawn

Tumor-Agnostic

Neoplasm Metastasis

NCT04542382 2025-03-30

BCRPmarker

Phase 1 Completed

11 enrolled

Healthy Volunteers

NCT06677957 2025-01-03

A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants

Phase 1 Completed

19 enrolled

Healthy Participants

NCT05926180 2024-12-13

Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)

Phase 1 Completed

25 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04094519 2024-11-20

A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer

Phase 1 Completed

24 enrolled

Genitourinary

Prostatic Neoplasms

NCT03864042 2024-09-27

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Phase 1 Completed

56 enrolled 158 charts

Dermatologic

Melanoma

NCT06329895 2024-07-05

A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants

Phase 1 Completed

15 enrolled

Thoracic

Advanced Non-small Cell Lung Cancer

NCT04887194 2024-05-08

PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

Phase 1 Completed

40 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT05395117 2023-12-13

A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin

Phase 1 Completed

32 enrolled

Healthy Participants

NCT05045638 2023-08-14

Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants

Phase 1 Completed

13 enrolled 14 charts

Healthy Participants

NCT04889287 2023-08-09

A Study to Learn How Much Rosuvastatin Gets Into the Blood When Taken With or Without Elinzanetant and to Learn About the Safety of Elinzanetant in Healthy Participants

Phase 1 Completed

16 enrolled

Endocrine

Multiple Endocrine Neoplasia Type 1

NCT03954366 2023-06-08

Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives

Phase 1 Completed

36 enrolled

Tumor-Agnostic

Neoplasms

NCT05708573 2023-04-14

Potential Drug Interaction Between ALXN2040 and Rosuvastatin

Phase 1 Completed

20 enrolled

Healthy Participants

NCT05368805 2022-10-06

Fruquintinib DDI Study With P-gp and BCRP Substrates

Phase 1 Completed

32 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04252300 2021-03-11

Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants

Phase 1 Completed

14 enrolled

Chronic Cough, Pain

NCT02626234 2020-12-10

A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors

Phase 1 Completed

32 enrolled

Other solid neoplasm

cMET-dysregulated Advanced Solid Tumors

NCT04621669 2020-11-09

Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin Hydrochloride

Phase 1 Unknown

18 enrolled

Drug-drug Interaction,SHR3680

NCT00966472 2020-04-21

Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC

Phase 1 Completed

24 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell

NCT02106845 2019-06-07

Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.

Phase 1 Completed

42 enrolled

Tumor-Agnostic

Neoplasms

NCT01051401 2018-08-01

Rosuvastatin in Treating Women With Cardiovascular Complications Who Are Undergoing Chemotherapy For Breast Cancer

Phase 1 Terminated

5 enrolled

Breast

Breast Neoplasms

NCT02317016 2018-07-31

Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer

Phase 1 Completed

44 enrolled 20 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02483871 2017-06-05

Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy

Phase 1 Withdrawn

Breast

Breast Neoplasms

NCT02671097 2016-09-08

Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate

Phase 1 Completed

30 enrolled

Healthy Volunteers

NCT02300363 2015-07-09

DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin

Phase 1 Completed

24 enrolled

Healthy